 |
N-[2,6-bis(1-methylethyl)phenyl]-N’-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt |
|---|---|
| Trade Name | |
| Orphan Indication | Congenital adrenal hyperplasia |
| USA Market Approval | USA |
| USA Designation Date | 2017-08-17 00:00:00 |
| Sponsor | Millendo Therapeutics, Inc.;301 North Main Street, Suite 100;Ann Arbor, Michigan, 48104 |
